Loading organizations...
Diagnoplex is a technology company.
Diagnoplex develops blood-based molecular diagnostic tests for non-invasive colorectal cancer screening. The company's clinical laboratory kits, including the Colox test, provide a less invasive alternative to traditional methods. This technology aims to improve patient compliance and broaden access to critical early detection for colorectal cancer.
Stavros Therianos founded Diagnoplex in 2005 in Lausanne, Switzerland. The company originated from the clear need for effective, non-invasive diagnostic tools to elevate early cancer detection rates. Therianos established the firm to apply molecular biology innovations, creating practical, patient-centric screening solutions for this pervasive disease.
Diagnoplex's products serve clinical laboratories and healthcare providers seeking accurate, non-invasive colorectal cancer screening. The company is committed to advancing personalized cancer care through accessible early detection. Its innovative testing portfolio aims to significantly enhance preventative medicine, improving health outcomes via prompt intervention.
Diagnoplex has raised $20.8M across 4 funding rounds.
Diagnoplex has raised $20.8M in total across 4 funding rounds.
Diagnoplex has raised $20.8M in total across 4 funding rounds.
Diagnoplex's investors include Debiopharm Diagnostics, Initiative Capital Romandie, NeoMed Management, Novartis Venture Fund, Omega Funds, Debiopharm, Novartis.
# Diagnoplex: High-Level Overview
Diagnoplex is a Swiss diagnostic technology company developing non-invasive blood biomarker tests for early cancer detection, with an initial focus on colorectal cancer screening.[1][3] The company builds molecular assays using single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) technology to identify cancer biomarkers in blood samples.[1] Diagnoplex addresses a critical healthcare gap: while survival rates for colorectal cancer improve dramatically—up to 90%—when detected early, current screening methods suffer from low compliance due to their invasive nature.[6] The company serves healthcare systems and diagnostic laboratories seeking to improve cancer detection rates through accessible, patient-friendly screening solutions.
Diagnoplex has demonstrated meaningful traction in the European market, securing multiple financing rounds and establishing strategic partnerships. The company closed a CHF 10 million funding round and has partnered with Unilabs, a leading European diagnostic provider, to scale its molecular assay capabilities across the continent.[1][5] This combination of proprietary technology, clinical validation, and distribution partnerships positions Diagnoplex as a growing player in the precision diagnostics space.
# Core Differentiators
# Role in the Broader Tech Landscape
Diagnoplex operates within the broader shift toward liquid biopsy and non-invasive diagnostics, a trend driven by advances in molecular biology and growing demand for patient-centric healthcare solutions. The timing is particularly favorable: healthcare systems across Europe face pressure to improve cancer screening rates while managing costs, and patients increasingly prefer non-invasive alternatives. Diagnoplex's focus on colorectal cancer—one of the most prevalent cancers globally—addresses a market with substantial unmet need and regulatory tailwinds supporting innovation in screening technologies.
# Quick Take & Future Outlook
Diagnoplex is well-positioned to capture market share in European cancer screening as healthcare providers seek to modernize their diagnostic capabilities. The company's success will likely depend on clinical validation through prospective studies, regulatory approvals across key European markets, and the ability to scale manufacturing and distribution through partnerships like Unilabs. As precision diagnostics become increasingly central to preventive healthcare, Diagnoplex's non-invasive biomarker platform could evolve beyond colorectal cancer into broader oncology screening applications, potentially expanding its addressable market significantly.
Diagnoplex has raised $20.8M across 4 funding rounds. Most recently, it raised $1.4M Other Equity in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 7, 2013 | $1.4M Other Equity | Debiopharm Diagnostics | Initiative Capital Romandie, NeoMed Management |
| Jun 1, 2013 | $1.0M Venture Round | Novartis Venture Fund, Omega Funds | |
| Jan 18, 2011 | $10.4M Series A Extension | Debiopharm | Initiative Capital Romandie, NeoMed Management, Novartis |
| Dec 1, 2008 | $8.0M Series A | Novartis Venture Fund, Omega Funds |